1.55 -0.14 (-8.28%)
After hours: 7:59PM EDT
|Bid||1.55 x 1000|
|Ask||1.79 x 2900|
|Day's Range||1.68 - 1.85|
|52 Week Range||1.62 - 10.25|
|Beta (3Y Monthly)||1.69|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.60|
OpGen, Inc. (OPGN) today announced that it has commenced an underwritten public offering of its common stock. All of the shares are being offered by OpGen, Inc. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds of this offering for research and development, including funding the continued development and manufacturing of its Acuitas® AMR Gene Panel tests, including its Acuitas AMR Gene Panel u5.47 that was released for Research Use Only in February 2018 and its Acuitas Lighthouse® software, to support acquisitions of products and technologies, capital expenditures, working capital and other general corporate purposes.
OpGen, Inc. (OPGN) today provided an update on its commercial activities and clinical trials for its Acuitas® AMR Gene Panel tests and the Acuitas Lighthouse® Software. Preliminary unaudited results for the third quarter of 2018 were also reported. OpGen continues to make commercial progress with the Acuitas AMR Gene Panel and the Acuitas Lighthouse Software Research Use Only (RUO) products.
GAITHERSBURG, Md., Sept. 25, 2018 -- OpGen, Inc. (NASDAQ: OPGN) announced today that Evan Jones, Chairman and Chief Executive Officer, will present a corporate overview at two.
OpGen, Inc. (OPGN) announced today a groundbreaking collaboration with the New York State Department of Health (“DOH”) and ILÚM Health Solutions, LLC (“ILÚM”), a wholly owned subsidiary of Merck’s Healthcare Services and Solutions, to develop a state-of-the-art research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide.
GAITHERSBURG, Md., Aug. 29, 2018-- OpGen, Inc. announced today that Evan Jones, Chairman and Chief Executive Officer, will present a corporate overview at the 20 th Annual Rodman & Renshaw Global Investment ...
Revenue increases 12% to $0.8 million, net loss narrows 21% to $3.3 million. Conference call begins at 4:30 p.m. Eastern time today. GAITHERSBURG, Md., Aug. 02, 2018-- OpGen, Inc. today reported financial ...
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / OpGen, Inc. (NASDAQ: OPGN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern Time. To listen ...
Zacks.com featured highlights include: Hilton Grand, Fastenal, Catalyst Biosciences, OpGen and ConforMIS
Generally, investors love stocks with a low price-to-earnings (P/E) ratio. The idea is that the lower the P/E, the higher will be the value of the stock. The simple logic that a stock’s current market price does not validate (is not equivalent to) its higher earnings and therefore has room to run justifies investors’ inclination toward low P/E stocks.Source: ©iStock.com/CharlieAJA
GAITHERSBERG, Md., July 25, 2018-- OpGen, Inc. today announced that the Company will report financial results for the three and six months ended June 30, 2018 after close of the U.S. financial markets ...
On Thursday, July 19, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: OraSure Technologies Inc. (NASDAQ: OSUR), ResMed Inc. (NYSE: RMD), OpGen Inc. (NASDAQ: OPGN), and Organovo Holdings Inc. (NASDAQ: ONVO). On Thursday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 373,287 shares.
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on ONVO sign up now at www.wallstequities.com/registration. Durham, North Carolina headquartered IQVIA Holdings Inc.'s stock finished Wednesday's session 1.31% higher at $100.48 with a total trading volume of 968,866 shares. Over the last month and the previous three months, the Company's shares have advanced 4.93% and 2.19%, respectively.
Newly public NeuroOne (NMTC) could be one of these movers in 2018 as they plan to file their first FDA medical device submission in the upcoming months. This technology addresses a large market opportunity and could support multiples of upside.